U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07459452) titled 'Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis' on Feb. 27.
Brief Summary: This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Perennial Allergic Rhinitis
Intervention:
BIOLOGICAL: JYB1904
Double-blind Induction Period: 150mg -450mg JYB1904 will be administered SC in Day1, Week 8 and Week 16.
Open-label Treatment Period: 300mg JYB1904 will be administered SC every 12 weeks (Q12W) from Week 24 to Week 48.
BIOLOGICAL: JYB1904
Double-blind Induction Peri...